Influence of Sodium Intake in spondyLoarthriTes
SALT
Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.
1 other identifier
interventional
250
1 country
4
Brief Summary
The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2024
Longer than P75 for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 30, 2024
CompletedFirst Submitted
Initial submission to the registry
January 31, 2024
CompletedFirst Posted
Study publicly available on registry
February 14, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
July 9, 2025
November 1, 2024
2.8 years
January 31, 2024
July 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
sodium intake
average sodium concentration in urine for the week
day of inclusion, monday and tuesday following
Study Arms (1)
Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis
OTHERPatients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis managed in the rheumatology departments of the study centres.
Interventions
measurement of salt intake without intervention
Eligibility Criteria
You may qualify if:
- patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis
- women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)
You may not qualify if:
- patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
- current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old.
- patients on systemic corticosteroids with corticosteroid therapy \> 10 mg prednisone equivalent
- pregnant woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
CHU Besançon
Besançon, 25000, France
CHD Vendée
La Roche-sur-Yon, 85000, France
CHU St Etienne
Saint-Etienne, 42000, France
Hôpital Nord Franche-Comté
Trévenans, 90400, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 31, 2024
First Posted
February 14, 2024
Study Start
January 30, 2024
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
May 1, 2027
Last Updated
July 9, 2025
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share